AIVITA Biomedical

Focus: AIVITA Biomedical is a newly founded (2023) stem cell and cell therapy company headquartered in Irvine, CA, focused on dendritic cell vaccines and cell-based therapeutics across oncology and infectious disease.

Cell Therapy Gene Therapy

Profile data last refreshed 2d ago · AI intelligence enriched 2w ago

Open Jobs

About AIVITA Biomedical

AI assessmentNot Hiring

No open roles listed right now. Follow AIVITA Biomedical to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

1/9 — Limited

Company HealthSolid

Pipeline

Mid-stage

2 Phase 3+

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Pipeline & Clinical Trials

melanoma cell lysate vaccine

Metastatic Melanoma

Phase 1

AV-MEL-1

Metastatic Melanoma

Phase 1

Clinical Trials (1)

Help build intelligence for AIVITA Biomedical

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Early-stage opportunity with a Phase 3 program (dendritic cell vaccine for glioblastoma) that could drive near-term clinical catalysts and value creation
Diverse pipeline across high-unmet-need oncology indications (glioblastoma, ovarian carcinoma, melanoma) plus a COVID-19 vaccine program with 5 active trials
Ground-floor role in cutting-edge cell therapy platform with potential to shape company culture, processes, and scientific direction from inception

Watch Out For

No active job openings currently listed and minimal publicly available staffing data raises questions about near-term hiring capacity and budget clarity
Pre-revenue, early-stage company with undisclosed funding and financial position introduces execution risk and potential runway concerns for long-term stability
Only 9 total clinical trials across the pipeline with modest Phase 3 depth (1 trial) may indicate earlier-than-expected stage relative to founding year

Generated by Claude from AIVITA Biomedical's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.